JP2007507538A - 疼痛軽減方法 - Google Patents

疼痛軽減方法 Download PDF

Info

Publication number
JP2007507538A
JP2007507538A JP2006534206A JP2006534206A JP2007507538A JP 2007507538 A JP2007507538 A JP 2007507538A JP 2006534206 A JP2006534206 A JP 2006534206A JP 2006534206 A JP2006534206 A JP 2006534206A JP 2007507538 A JP2007507538 A JP 2007507538A
Authority
JP
Japan
Prior art keywords
ziconotide
morphine
conopeptide
analgesic
intrathecal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006534206A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007507538A5 (enExample
Inventor
デイビッド・ジェイ・エリス
ジョージ・ミルジャニッチ
デイビッド・シールズ
Original Assignee
エラン ファーマシューティカルズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エラン ファーマシューティカルズ，インコーポレイテッド filed Critical エラン ファーマシューティカルズ，インコーポレイテッド
Publication of JP2007507538A publication Critical patent/JP2007507538A/ja
Publication of JP2007507538A5 publication Critical patent/JP2007507538A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2006534206A 2003-10-02 2004-10-01 疼痛軽減方法 Pending JP2007507538A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50862503P 2003-10-02 2003-10-02
US50846903P 2003-10-03 2003-10-03
PCT/US2004/032559 WO2005032556A1 (en) 2003-10-02 2004-10-01 Method for reducing pain

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011129404A Division JP2011173931A (ja) 2003-10-02 2011-06-09 疼痛軽減方法

Publications (2)

Publication Number Publication Date
JP2007507538A true JP2007507538A (ja) 2007-03-29
JP2007507538A5 JP2007507538A5 (enExample) 2007-11-08

Family

ID=34426056

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006534206A Pending JP2007507538A (ja) 2003-10-02 2004-10-01 疼痛軽減方法
JP2011129404A Pending JP2011173931A (ja) 2003-10-02 2011-06-09 疼痛軽減方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011129404A Pending JP2011173931A (ja) 2003-10-02 2011-06-09 疼痛軽減方法

Country Status (5)

Country Link
US (14) US7268109B2 (enExample)
EP (1) EP1689401A1 (enExample)
JP (2) JP2007507538A (enExample)
CA (2) CA2930900C (enExample)
WO (1) WO2005032556A1 (enExample)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
EP1531791B1 (en) 2002-06-07 2010-08-11 Dyax Corp. Prevention and reduction of ischemia
CA2496789C (en) 2002-08-28 2013-12-17 Dyax Corp. Methods for preserving organs and tissues
JP2007507538A (ja) 2003-10-02 2007-03-29 エラン ファーマシューティカルズ，インコーポレイテッド 疼痛軽減方法
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US7776365B2 (en) * 2005-03-18 2010-08-17 Sakura Properties, Llc Article with skin protecting and moisturizing compound
US20060210697A1 (en) * 2005-03-18 2006-09-21 Mower Thomas E Infant formula composition
US7749545B2 (en) 2005-03-18 2010-07-06 Sakura Properties, Llc Fucoidan compositions and methods for dietary and nutritional supplements
US20060210688A1 (en) * 2005-03-18 2006-09-21 Mower Thomas E Dehydrated sports drink powder
US20060210496A1 (en) * 2005-03-18 2006-09-21 Mower Thomas E Compositions for skin protection from ultraviolet damage
US20060210692A1 (en) * 2005-03-18 2006-09-21 Mower Thomas E Baby food composition
US7666448B2 (en) * 2005-03-18 2010-02-23 Sakura Properties, Llc Skin cleansing article
US20070020358A1 (en) * 2005-03-18 2007-01-25 Mower Thomas E Sports drink concentrate
EP1877968A2 (en) * 2005-04-12 2008-01-16 Alianna J. Maren System and method for evidence accumulation and hypothesis generation
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8202535B2 (en) 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US20090209480A1 (en) * 2006-01-17 2009-08-20 The Regents Of The University Of Colorado Central administration of stable formulations of therapeutic agents for cns conditions
US8536445B2 (en) * 2006-06-02 2013-09-17 Emcore Solar Power, Inc. Inverted metamorphic multijunction solar cells
US20080102097A1 (en) * 2006-10-31 2008-05-01 Zanella John M Device and method for treating osteolysis using a drug depot to deliver an anti-inflammatory agent
CN101820838B (zh) * 2007-08-07 2013-06-05 阿塞尔Rx制药有限公司 采用口腔经粘膜剂型的用于程序镇静和镇痛的组合物和方法
JP2010536883A (ja) * 2007-08-23 2010-12-02 ジェンザイム・コーポレーション カリクレイン阻害剤を用いた治療
US8470360B2 (en) 2008-04-18 2013-06-25 Warsaw Orthopedic, Inc. Drug depots having different release profiles for reducing, preventing or treating pain and inflammation
CN101412752B (zh) * 2007-12-26 2011-12-07 杭州诺泰制药技术有限公司 齐考诺肽的固相合成方法
US9610243B2 (en) 2008-04-18 2017-04-04 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
US8883768B2 (en) * 2008-04-18 2014-11-11 Warsaw Orthopedic, Inc. Fluocinolone implants to protect against undesirable bone and cartilage destruction
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
US20090264477A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc., An Indiana Corporation Beta adrenergic receptor agonists for treatment of pain and/or inflammation
US9072727B2 (en) 2008-04-18 2015-07-07 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of degenerative disc disease
US8557273B2 (en) * 2008-04-18 2013-10-15 Medtronic, Inc. Medical devices and methods including polymers having biologically active agents therein
US8420114B2 (en) * 2008-04-18 2013-04-16 Warsaw Orthopedic, Inc. Alpha and beta adrenergic receptor agonists for treatment of pain and / or inflammation
US20090263451A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Anti-Inflammatory and/or Analgesic Agents for Treatment of Myofascial Pain
US9132119B2 (en) * 2008-04-18 2015-09-15 Medtronic, Inc. Clonidine formulation in a polyorthoester carrier
US20090263489A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Analgesic and anti-inflammatory compositions and methods for reducing, preventing or treating pain and inflammation
US20090264489A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Method for Treating Acute Pain with a Formulated Drug Depot in Combination with a Liquid Formulation
US8722079B2 (en) * 2008-04-18 2014-05-13 Warsaw Orthopedic, Inc. Methods for treating conditions such as dystonia and post-stroke spasticity with clonidine
US8946277B2 (en) 2008-04-18 2015-02-03 Warsaw Orthopedic, Inc. Clonidine formulations in a biodegradable polymer carrier
US8629172B2 (en) 2008-04-18 2014-01-14 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising clonidine
US9132085B2 (en) 2008-04-18 2015-09-15 Warsaw Orthopedic, Inc. Compositions and methods for treating post-operative pain using clonidine and bupivacaine
US8889173B2 (en) * 2008-04-18 2014-11-18 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of pain and/or inflammation
US8956641B2 (en) * 2008-04-18 2015-02-17 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of inflammatory diseases
US20110129508A1 (en) * 2008-05-06 2011-06-02 Relevare Aust. Pty Ltd Methods and compositions for the management of pain using omega-conotoxins
US20110171163A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of ziconotide peptides
US8680263B2 (en) 2008-09-19 2014-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
US20100098746A1 (en) * 2008-10-20 2010-04-22 Warsaw Orthopedic, Inc. Compositions and methods for treating periodontal disease comprising clonidine, sulindac and/or fluocinolone
US8945592B2 (en) * 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
US8822546B2 (en) * 2008-12-01 2014-09-02 Medtronic, Inc. Flowable pharmaceutical depot
US8637454B2 (en) 2009-01-06 2014-01-28 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
US20100228097A1 (en) * 2009-03-04 2010-09-09 Warsaw Orthopedic, Inc. Methods and compositions to diagnose pain
US20100239632A1 (en) 2009-03-23 2010-09-23 Warsaw Orthopedic, Inc. Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
PL387984A1 (pl) * 2009-05-07 2010-11-08 Instytut Medycyny Doświadczalnej I Klinicznej Im. Mirosława Mossakowskiego Pan Nowe kompozycje substancji leczniczych do leczenia bólów przewlekłych
US8617583B2 (en) * 2009-07-17 2013-12-31 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for prevention or treatment of a hematoma, edema, and/or deep vein thrombosis
US8231891B2 (en) * 2009-07-31 2012-07-31 Warsaw Orthopedic, Inc. Implantable drug depot for weight control
US20110091544A1 (en) * 2009-10-16 2011-04-21 Acelrx Pharmaceuticals, Inc. Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting
US20110097375A1 (en) 2009-10-26 2011-04-28 Warsaw Orthopedic, Inc. Formulation for preventing or reducing bleeding at a surgical site
ES2905545T3 (es) 2010-01-06 2022-04-11 Takeda Pharmaceuticals Co Proteínas de unión a calicreína plasmática
DE102010053416A1 (de) 2010-12-03 2012-06-06 Friedrich-Schiller-Universität Jena Verfahren zur Synthese von Cystein-haltigen Peptiden durch Native Chemische Ligation und/oder Oxidation
KR102107695B1 (ko) 2011-01-06 2020-05-07 다이액스 코포레이션 혈장 칼리크레인 결합 단백질
JP2013037571A (ja) 2011-08-09 2013-02-21 Sony Corp 情報処理装置、情報処理方法、プログラム、及び情報処理システム
US9180108B2 (en) 2011-10-27 2015-11-10 Medtronic, Inc. Baclofen formulations and methods for making same
US9155734B2 (en) 2012-03-07 2015-10-13 Mallinckrodt Llc Stability of hydromorphone hydrochloride solutions
EP2928919A2 (en) 2012-12-04 2015-10-14 AbbVie Inc. Blood-brain barrier (bbb) penetrating dual specific binding proteins
EP2948475A2 (en) 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
US20140296830A1 (en) * 2013-03-28 2014-10-02 Jazz Pharmaceuticals, Inc. Methods of administering drugs in an implantable multi-chamber pump
JP6246640B2 (ja) * 2014-03-25 2017-12-13 京セラ株式会社 電子機器
IL247942B (en) 2014-03-27 2022-09-01 Dyax Corp Compositions and methods for drops in macular edema as a result of diabetes
BR102015010089A2 (pt) * 2015-05-04 2017-07-18 Ministério Da Ciência E Tecnologia Process for obtaining a product for prevention, paralysis of care injuries and remineralization of teeth and obtained product
CA2986704C (en) 2015-05-22 2022-03-01 Clemson University Research Foundation Conotoxin peptides for use in biofouling deterrence
CA2994447A1 (en) 2015-12-11 2017-06-15 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US10369157B1 (en) 2018-03-29 2019-08-06 Mfkc 200, Llc Multi-agent formulation
BR112021013766A2 (pt) 2019-03-01 2021-09-21 Flamel Ireland Limited Composições de gama-hidroxibutirato com farmacocinética melhorada no estado alimentado
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63122623A (ja) * 1986-10-31 1988-05-26 ユーロセルテイツク・エス・アー 徐放性ヒドロモルホン組成物
US5364842A (en) * 1991-12-30 1994-11-15 Neurex Corporation Method of producing analgesia
US6136786A (en) * 1991-12-30 2000-10-24 Elan Pharmaceuticals, Inc. Method for enhancing analgesia
WO2001076576A2 (en) * 2000-04-07 2001-10-18 Pfizer Products Inc. A pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
WO2001083555A2 (en) * 2000-05-04 2001-11-08 California Institute Of Technology Pain signaling molecules
WO2003078408A1 (en) * 2002-03-15 2003-09-25 Pharmacia Corporation Crystalline parecoxib sodium

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5051403A (en) 1989-11-22 1991-09-24 Neurex Corporation Method of treating ischemia-related neuronal damage
US5559095A (en) 1989-11-22 1996-09-24 Neurex Corporation Delayed treatment method of reducing ischemia-related neuronal damage
US5189020A (en) 1989-11-22 1993-02-23 Neurex Corporation Method of reducing neuronal damage using omega conotoxin peptides
US5471033A (en) * 1994-04-15 1995-11-28 International Business Machines Corporation Process and apparatus for contamination-free processing of semiconductor parts
EP0808153B1 (en) * 1995-02-10 1999-08-04 Medtronic, Inc. Method and device for administering analgesics
US6054429A (en) 1996-03-08 2000-04-25 Elan Pharmaceuticals, Inc. Epidural method of producing analgesia
EP0835126B1 (en) 1995-06-27 2003-04-02 Elan Pharmaceuticals, Inc. Compositions and formulations for producing analgesia and for inhibiting progression of neuropathic pain disorders
US5795864A (en) 1995-06-27 1998-08-18 Neurex Corporation Stable omega conopetide formulations
US6379882B1 (en) 1998-09-14 2002-04-30 Elan Pharmaceuticals, Inc. Method for selecting compounds for treating ischemia-related cellular damage
JP2007507538A (ja) * 2003-10-02 2007-03-29 エラン ファーマシューティカルズ，インコーポレイテッド 疼痛軽減方法
US20140296830A1 (en) * 2013-03-28 2014-10-02 Jazz Pharmaceuticals, Inc. Methods of administering drugs in an implantable multi-chamber pump

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63122623A (ja) * 1986-10-31 1988-05-26 ユーロセルテイツク・エス・アー 徐放性ヒドロモルホン組成物
US5364842A (en) * 1991-12-30 1994-11-15 Neurex Corporation Method of producing analgesia
US6136786A (en) * 1991-12-30 2000-10-24 Elan Pharmaceuticals, Inc. Method for enhancing analgesia
WO2001076576A2 (en) * 2000-04-07 2001-10-18 Pfizer Products Inc. A pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
WO2001083555A2 (en) * 2000-05-04 2001-11-08 California Institute Of Technology Pain signaling molecules
WO2003078408A1 (en) * 2002-03-15 2003-09-25 Pharmacia Corporation Crystalline parecoxib sodium

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
JPN6010052780; ＷＡＮＧ，Ｙ．Ｘ．　ｅｔ　ａｌ: 'Ｉｎｔｅｒａｃｔｉｏｎｓ　ｏｆ　ｉｎｔｒａｔｈｅｃａｌｌｙ　ａｄｍｉｎｉｓｔｅｒｅｄ　ｚｉｃｏｎｏｔｉｄｅ，　ａ　ｓｅｌｅｃｔｉｖｅ　ｂｌｏｃｋｅｒ　ｏｆ　ｎｅｕｒｏｎａｌ　Ｎ-ｔｙｐｅ　ｖｏｌｔａｇ' Ｐａｉｎ Ｖｏｌ．８４，　Ｎｏ．２-３, 2000, ｐ．２７１-８１ *
JPN6010052781; ＷＥＩ，Ｚ．Ｙ．　ｅｔ　ａｌ: 'Ｓｐｉｎａｌ　ｍｏｒｐｈｉｎｅ／ｃｌｏｎｉｄｉｎｅ　ａｎｔｉｎｏｃｉｃｅｐｔｉｖｅ　ｓｙｎｅｒｇｉｓｍ：　ｉｎｖｏｌｖｅｍｅｎｔ　ｏｆ　Ｇ　ｐｒｏｔｅｉｎｓ　ａｎｄ　Ｎ-ｔｙｐｅ　ｖｏｌｔａｇｅ-ｄｅ' Ｊ　Ｐｈａｒｍａｃｏｌ　Ｅｘｐ　Ｔｈｅｒ Ｖｏｌ．２７８，　Ｎｏ．３, 1996, ｐ．１３９２-４０７ *
JPN6010052782; ＨＯＲＶＡＴＨ，Ｇ．　ｅｔ　ａｌ: 'Ｒｏｌｅ　ｏｆ　ｃａｌｃｉｕｍ　ｃｈａｎｎｅｌｓ　ｉｎ　ｔｈｅ　ｓｐｉｎａｌ　ｔｒａｎｓｍｉｓｓｉｏｎ　ｏｆ　ｎｏｃｉｃｅｐｔｉｖｅ　ｉｎｆｏｒｍａｔｉｏｎ　ｆｒｏｍ　ｔｈｅ　ｍｅｓｅｎｔｅｒｙ' Ｐａｉｎ Ｖｏｌ．９３，　Ｎｏ．１, 2001, ｐ．３５-４１ *
JPN6013050164; Ｎｅｕｒｏｓｕｒｇｅｒｙ Ｖｏｌ．４４，Ｎｏ．２, 1999, ｐ２８９-３０１
JPN6013050165; Ｒｅｇｉｏｎａｌ　Ａｎｅｓｔｈｅｓｉａ　ａｎｄ　Ｐａｉｎ　Ｍｅｄｉｃｉｎｅ Ｖｏｌ．３５，Ｎｏ．３, 2000, ｐ２７４-２７８
JPN6013050166; Ｔｈｅ　Ｃｌｉｎｉｃａｌ　Ｊｏｕｒｎａｌ　ｏｆ　Ｐａｉｎ Ｖｏｌ．１３，Ｎｏ．３, 1997, ｐ２５６-２５９
JPN6013050167; Ａｒｚｎｅｉｍｉｔｔｅｌ-Ｆｏｒｓｃｈｕｎｇ　Ｄｒｕｇ　Ｒｅｓｅａｒｃｈ Ｖｏｌ．４９，Ｎｏ．６, 1999, ｐ４８９-４９３
JPN6013050168; 医薬品添加物事典２０００ , 20000428, ｐ２８１, 株式会社薬事日報社
JPN6013051483; Ｄｒｕｇｓ　ｉｎ　Ｒ＆Ｄ Ｖｏｌ．１　Ｎｏ．１, 199901, ｐ４６-４８

Also Published As

Publication number Publication date
US20110021436A1 (en) 2011-01-27
US8268774B2 (en) 2012-09-18
CA2540895A1 (en) 2005-04-14
US20110021437A1 (en) 2011-01-27
US8765680B2 (en) 2014-07-01
US7833973B2 (en) 2010-11-16
US7524812B2 (en) 2009-04-28
US20150374787A1 (en) 2015-12-31
US20090247452A1 (en) 2009-10-01
US20140371153A1 (en) 2014-12-18
US20190255148A1 (en) 2019-08-22
US7268109B2 (en) 2007-09-11
US9707270B2 (en) 2017-07-18
US7977307B2 (en) 2011-07-12
US20120003290A1 (en) 2012-01-05
WO2005032556A1 (en) 2005-04-14
EP1689401A1 (en) 2006-08-16
US20070270353A1 (en) 2007-11-22
US20140107038A1 (en) 2014-04-17
US8513198B2 (en) 2013-08-20
JP2011173931A (ja) 2011-09-08
CA2930900C (en) 2018-10-16
US7956030B2 (en) 2011-06-07
US20130096066A1 (en) 2013-04-18
US20130225499A1 (en) 2013-08-29
CA2540895C (en) 2016-08-02
US8653033B2 (en) 2014-02-18
US20070269528A1 (en) 2007-11-22
US20170312337A1 (en) 2017-11-02
US10307463B2 (en) 2019-06-04
CA2930900A1 (en) 2005-04-14
US10857204B2 (en) 2020-12-08
US20050192218A1 (en) 2005-09-01

Similar Documents

Publication Publication Date Title
US10857204B2 (en) Method for administering omega-conopeptide
US10952976B2 (en) Compositions and methods for treating respiratory depression with fenfluramine
Khatri et al. Xylazine suppresses fentanyl consumption during self-administration and induces a unique sex-specific withdrawal syndrome that is not altered by naloxone in rats.
MXPA02003670A (es) Sales y bases de 17-(ciclopropilmetil)-4,5 alfa-epoxi-6-metilenomorfinan-3,14 diol para optimizar la homeostasis de dopamina durante la administracion de analgesicos.
JP2024506861A (ja) 物質使用障害の治療のための隔離化合物及びその使用
US20180028594A1 (en) Peripheral kappa opioid receptor agonists for hard tissue pain
JP2021511338A (ja) 睡眠障害の治療及び予防
JP2004529959A (ja) 鎮痛剤組成物と手法
JP2018515547A (ja) オピオイドとｎ−アシルエタノールアミンの組み合わせ
EP3765056B1 (en) Compositions, methods and uses of a teneurin c-terminal associated peptide-1 (tcap-1) for treating opioid addiction
JP2024165960A (ja) 急性痛の治療剤
US20250345324A1 (en) Combination formulations of naloxone and atipamezole
HK40046105B (en) Compositions, methods and uses of a teneurin c-terminal associated peptide-1 (tcap-1) for treating opioid addiction
HK40046105A (en) Compositions, methods and uses of a teneurin c-terminal associated peptide-1 (tcap-1) for treating opioid addiction
CN101151051A (zh) 钠通道阻断剂及其衍生物与阿片受体拮抗剂的联合制剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070921

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100921

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20101025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20101025

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101221

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110121

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110609

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110705

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20110729